LEAKED BENCHMARKS for AMD's forthcoming Raven Ridge APUs suggest that upcoming devices, expected to be launched in time for Christmas, will outperform current Bristol Ridge APUs by up to 90 per cent on multicore applications.
According to WCCFTech, scores for the AMD Ryzen 5 2500U indicate that, compared to the current AMD A12-9800B APU, the new processor is more than 50 per cent faster in terms of single-core performance, and around 90 per cent faster on multi-core workloads.
The leaked benchmarks for the AMD part shows a score of 3,625 on Geekbench for single-core performance and a score of 9,723 for multi-core. That compares with scores of 2,315 and 5,115, respectively, for an HP Elitebook 745 G4 packing the AMD Pro A12-9800B four-core Bristol Ridge APU.
The Raven Ridge APUs will be the first integrated devices featuring a combination of AMD's Zen microarchitecture, which it launched in March this year, and its Vega graphics processing unit (GPU) microarchitecture, which it released this summer.
Information released by AMD earlier this year suggests that the new APUs ought to provide at least a 50 per cent boost to CPU performance while consuming half the power. The new devices are expected to appear first in low-end and mid-range laptops.
Both Zen and Vega are designed to run on a 14nm process architecture, compared to their predecessor technology's 28nm. While Zen, in the form of Ryzen desktop CPUs, have been well received, the reception for Vega has been more muted, with debut devices not providing the big performance leap over rival Nvidia many had expected.
On top of that, AMD's preference for HDM memory over GDDR5 has also added to the cost of graphics cards based on Vega, while bitcoin miners have also snapped up much of the early production, forcing mainstream buyers either to pay a premium for AMD's latest graphics cards - or buy cards by Nvidia instead. µ
No Roger the Racist Robot
It's not who I am wearing underneath, but what I do on IFTTT defines me
But there's no indication that data was used for nefarious purposes
But firm maintains that it received no selective treatment